Etoricoxib dispersible tablets and preparation method thereof

A technology for etoricoxib and dispersible tablets, applied in the field of etoricoxib dispersible tablets and preparation thereof, can solve problems such as low dissolution, and achieve the effects of promoting absorption, enhancing medication compliance, and improving bioavailability
CN104586799AInactive Publication Date: 2015-05-06万全万特制药江苏有限公司

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
万全万特制药江苏有限公司
Publication Date
2015-05-06
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The invention discloses etoricoxib dispersible tablets and a preparation method thereof. The etoricoxib dispersible tablets are prepared by the following steps: by adopting etoricoxib as an active pharmaceutical ingredient, dissolving the active pharmaceutical ingredient and carriers in a solvent, adopting a pressure reducing and drying or spraying and drying technology to prepare into solid dispersion bodies, and then using the solid dispersion bodies to prepare into the dispersible tablets. The etoricoxib dispersible tablets disclosed by the invention have the advantages that the etoricoxib and a proper amount of carriers are adopted to be prepared into the solid dispersion bodies, so that the solubility and the dissolving-out speed of medicines are increased, the absorption of the medicines in a body is enhanced, and the bioavailability of the medicines is improved; and simultaneously, the solid dispersion bodies are prepared into the dispersible tablets, so that the compliance of administration of a patient is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a pharmaceutical preparation in the category of oral rapid release, in particular to an etoricoxib dispersible tablet and a preparation method thereof. Background technique

[0002] Etoricoxib, chemical name is 5-chloro-6-methyl-3[4-(methylsulfonyl)phenyl]-2,3-bipyridine, molecular formula: C 18 h 15 CIN 2 o 2 S, molecular weight: 358.84, its structure is as follows:

[0003] .

[0004] Etoricoxib is a new type of highly selective COX-2 inhibitor, and its selective inhibitory effect on COX-2 is 100 times that of COX-1; in vitro studies have shown that etoricoxib has a strong selective effect on COX-2 than any other currently available COX-2 selective inhibitor. Etoricoxib has been approved for the treatment of osteoarthritis by more than 80 countries in Europe, Latin America, and Asia Pacific, and the recommended dose is 30 mg and 60 mg, once a day. A number of clinical studies have shown that the therapeutic effect of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More